ACM
IBRX icon

Altium Capital Management’s ImmunityBio IBRX Stock Holding History

Altium Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,060,000
Closed -$2.71M – 47
2024
Q4 		$2.71M Buy
+1,060,000
New +$4.42M 0.77% 42

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Altium Capital Management's IBRX Position: Q1 2025 in Review

Altium Capital Management sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 1,060,000 shares — an estimated $2.71M sold.

Altium Capital Management first reported a position in IBRX in Q4 2024 and held it in 1 quarter. The position peaked at $2.71M in Q4 2024. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

  • Altium Capital Management reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 1,060,000 ImmunityBio shares in Q1 2025, an estimated $2.71M.
  • Altium Capital Management first reported a position in ImmunityBio in Q4 2024 and held it in 1 quarter.
  • Altium Capital Management's ImmunityBio position peaked at $2.71M in Q4 2024.
  • 210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.